SaferSkin™

SaferSkin

Details

DC Role: 
Developer
Duration: 
On going
Client: 
Open for Market

ABOUT THIS PROJECT


SaferSkin™, a powerful new test for skin sensitisation

SaferSkin™ combines three of the top methods for ITS: the Bayesian Network approach, Multiple Regression Analysis and ‘2 out of 3‘ Weight of Evidence.

For decades, animal testing was the only method for testing the potential for skin sensitisation. Today, Integrated Testing Strategies (ITS) combining in silico computer models and in vitro data offer a much better way. In short, if a similar compound is already known to cause sensitisation, the computer model can predict the probability that a new compound could as well. Today, by combining in silico and in vitro technology, scientists can weed out risks before a compound reaches consumers.

Edelweiss Connect’s new SaferSkin™ app industrializes the ITS developed at Procter & Gamble (P&G) and other large consumer product companies for skin sensitivity*. In keeping with Edelweiss Connect’s track record in collaborative scientific communities, we initially worked with P&G to make their approach, designed to respond to that company’s particular needs, relevant to all researchers. In addition, we made SaferSkin™ user-friendly, free and open-access.

New technology, new paradigm

SaferSkin™ combines three of the top methods for ITS: the Bayesian Network approach, Multiple Regression Analysis and ‘2 out of 3‘ Weight of Evidence. “SaferSkin™ is like a legal team that brings in all the evidence, so the jury can reach a verdict they are confident about,” explains Dr. Barry Hardy, CEO, Edelweiss Connect.

To pack even more power into SaferSkin™, Edelweiss Connect partnered with Eurosafe, global suppliers of biological assays, to add genomics data from the Sens-IS assay. “Sens-IS is a leading assay on the market that is genomics-based and covers many key events in skin sensitisation,” explains Dr. Christophe Chesne, CEO of Eurosafe and Biopredic International.

“The promise of this combined expertise is what motivates Edelweiss Connect,” says Dr. Hardy. “We aim to be at the front of this paradigm change, helping companies reduce, refine and replace toxicology testing on animals and make sure their products are safe. We believe these two goals are complimentary.”

*doi: 10.1007/s00204-015-1634-2

 

Latest Tweets

Edelweiss Connect (2 weeks ago)
RT @EU_ToxRisk: The EU-ToxRisk NAM-based Testing Commercialization Platform presented during the @EU_ToxRisk Open Symposium, Feb 12, 2020 i…
Edelweiss Connect (2 weeks ago)
RT @Biopredic_Intl: We are glad to announce the launch of the new HepaRG #logo !! Worldwide recognized and quite unique human hepatic stem…
Edelweiss Connect (3 weeks ago)
The SafeDESIgn imaging-based toxicity reporter platform for chemical safety assessment #SaferWorldbyDesign… https://t.co/7xeN1d6w6t
Edelweiss Connect (5 weeks ago)
The latest #OpenTox webinar focused on #AOPs current trends and developments, presented by Tatyana Doktorova https://t.co/ZKj5PivfiN
Edelweiss Connect (5 weeks ago)
RT @barryhardy: Tatyana Doktorova will discuss current trends and developments in Adverse Outcome Pathways as exemplified by case studies (…

Get in touch

  • Address: Edelweiss Connect GmbH
    Technology Park Basel
    Hochbergerstrasse 60C
    CH-4057 Basel / Basel-Stadt
    Switzerland

USA office

  • Address: Edelweiss Connect Inc
    Research Triangle Park NC
    800 Park Offices Dr
    Durham, NC 27709
    USA